Saxenda Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of obesity and overweight conditions, rising awareness of weight-related comorbidities, expansion of specialist obesity clinics, growing physician acceptance of injectable therapies, improved reimbursement coverage.

The growth in the forecast period can be attributed to increasing demand for long-term weight loss solutions, rising focus on metabolic health management, expansion of digital weight management programs, growing investments in obesity drug development, increasing patient adherence to injectable therapies. Major trends in the forecast period include increasing adoption of glp-1 receptor agonists, rising demand for pharmacological weight management, growing preference for injectable obesity treatments, expansion of long-term obesity care programs, enhanced focus on appetite regulation therapies.

The rising prevalence of obesity is expected to drive the growth of the Saxenda market going forward. Obesity is a health condition characterized by excess body fat, which increases the risk of conditions such as diabetes, heart disease, and certain cancers. The growing prevalence of obesity is attributed to factors including unhealthy diets, sedentary lifestyles, urbanization, genetic predisposition, and hormonal imbalances. Saxenda aids in weight management through its active ingredient, liraglutide, which mimics the natural hormone GLP-1 to promote feelings of fullness, reduce caloric intake, and support sustainable weight loss when combined with a balanced diet and regular exercise. For instance, in May 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between 2022 and 2023, approximately 64% of adults aged 18 and over in England were classified as overweight or obese. Therefore, the rising prevalence of obesity is driving the growth of the Saxenda market.

The rising prevalence of diabetes is expected to propel the growth of the Saxenda market going forward. Diabetes is a chronic condition that affects the body’s ability to regulate blood sugar (glucose) levels. The increasing prevalence of diabetes is driven by factors such as unhealthy diets, sedentary lifestyles, obesity, aging populations, and genetic predisposition. Saxenda supports diabetes management through liraglutide, which enhances insulin sensitivity, regulates blood sugar levels, and slows gastric emptying, providing both glycemic control and weight management benefits. For instance, in February 2023, Diabetes Canada, a national charitable organization, reported that nearly 30% of Ontario’s population - around 2.4 million people - lived with diabetes or prediabetes, with a projected 25% increase over the next decade, raising annual treatment costs from $1.7 billion to $2.1 billion by 2033. Therefore, the rising prevalence of diabetes is driving the growth of the Saxenda market.

Key companies in the Saxenda market are focusing on innovative products, such as generic formulations for weight management, to increase accessibility and affordability. Generic weight management products are chemically equivalent to brand-name drugs, providing the same therapeutic effects at a lower cost. For instance, in April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its generic liraglutide formulation, gSaxenda. Available as a 6 mg/ml solution in a pre-filled pen, this product is designed to support weight management alongside a reduced-calorie diet and increased physical activity. The approval underscores the importance of cost-effective alternatives in addressing obesity, further strengthening Biocon’s portfolio of complex, vertically integrated drug products.

Major companies operating in the saxenda market are Novo Nordisk.

North America was the largest region in the saxenda market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the saxenda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the saxenda market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the saxenda market by increasing costs of imported active pharmaceutical ingredients, peptide synthesis materials, injection device components, and cold-chain logistics infrastructure. North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces increased manufacturing and export costs. These tariffs are elevating drug prices and affecting patient affordability. However, they are also encouraging regional production of injectable therapies, localized device manufacturing, and long-term investments in domestic pharmaceutical supply chains.

The saxenda market research report is one of a series of new reports that provides saxenda market statistics, including saxenda industry global market size, regional shares, competitors with a saxenda market share, detailed saxenda market segments, market trends and opportunities, and any further data you may need to thrive in the saxenda industry. This saxenda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Saxenda is a prescription medication containing liraglutide, used to support weight management in adults with obesity or overweight conditions. It works by mimicking a naturally occurring hormone that regulates appetite, helping individuals reduce caloric intake and achieve sustained weight loss when combined with a reduced-calorie diet and increased physical activity.

The primary indications for Saxenda include obesity management (body mass index [BMI] ≥30 kg/m²) and overweight management (BMI 27-< 30 kg/m² with weight-related comorbidities). Obesity is defined by a BMI of 30 kg/m² or higher, reflecting excessive body fat accumulation, which increases the risk of chronic conditions such as type 2 diabetes, hypertension, and cardiovascular disease. Saxenda is available in injection and prefilled pen formulations and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, and homecare settings.

The saxenda market consists of sales of products such as prefilled pens of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.